

**PCR-/NAT VRE**  
**(RV 546) November 2024**



**Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.**

*Sample composition and expected results.*

Proben Nr.	Erwartet / <i>expected</i>		Probenzusammensetzung / <i>Sample composition</i>
546A 241015 01	+++	61 / 72	<i>Enterococcus faecium</i> <b>vanB</b> (~ 1x10 <sup>6</sup> CFU/mL)
546A 241015 02	∅	62	<i>Enterococcus faecium</i> vanA/vanB neg (~ 5x10 <sup>5</sup> CFU/mL)
546A 241015 03	∅	62	<i>Escherichia coli</i> K12
546A 241015 04	++	61 / 71	<i>Enterococcus faecalis</i> <b>vanA</b> (~ 5x10 <sup>4</sup> CFU/mL)

**Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.**

*Absolute numbers of reported individual results.*

<i>n</i> = 77	Proben Nr. ( <i>Sample no.</i> )					Inhibition			
	01	02	03	04		01	02	03	04
<b>Befund</b> <i>Result</i>									
<b>Positiv</b>	77	0	0	74	n.d.	1	1	1	1
<b>Negativ</b>	0	77	76	3	nein <i>no</i>	76	76	75	76
<b>Fraglich</b> <i>Questionable</i>	0	0	1	0	ja <i>yes</i>	0	0	1	0

**Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.**

*Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.*

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>				NAT richtig negativ <i>True negative results</i>			
	01		04		02		03	
	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%
Amplex eazyplex VRE (n= 4)	4	100	4	100	4	100	4	100
Amplex eazyplex VREbasic (n= 7)	7	100	7	100	7	100	7	100
AmpliGnost Vancomycin A/B (n= 3)	3	100	3	100	3	100	3	100
BioGx Vancomycin resistance (n= 2)	2	100	2	100	2	100	2	100
Bruker-HAIN GenoType Enteroc. (n= 11)	11	100	11	100	11	100	11	100
Cepheid Xpert vanA / vanB (n= 25)	25	100	25	100	25	100	25	100
ampliCube MDR Panel1-6 (n= 1)	1	100	1	100	1	100	1	100
Seegene Allplex Entero-DR (n= 9)	9	100	8	89	9	100	9	100

<b>In house PCR assay (n= 14)</b>	<b>14</b>	<b>100</b>	<b>12</b>	<b>86</b>	<b>14</b>	<b>100</b>	<b>13<sup>§</sup></b>	<b>93</b>
<b>Other commercial tests (n= 1)</b>	<b>1</b>	<b>100</b>	<b>1</b>	<b>100</b>	<b>1</b>	<b>100</b>	<b>1</b>	<b>100</b>

The following tests are listed under "Other commercial tests": Roche UC-TIB-VRE (vanA/B) (1x).

§ Fraglich *Due to reporting questionable results, the number of true results has been reduced.*

**Comments:**

1. Seventy-five participants reported dedicated vanA / vanB identification. All reported results were correct.